10.03.2021 • NewsAmgenMergers & Acquisitions (M&A)

Amgen Boosts Oncology Portfolio with Five Prime Buy

Amgen is to buy Five Prime Therapeutics, a clinical-stage biotech focused on developing immuno-oncology and targeted cancer therapies, for about $1.9 billion. The transaction is expected to close by the end of the second quarter, when a wholly owned subsidiary of Amgen will merge with Five Prime.

“The acquisition of Five Prime offers a compelling opportunity for Amgen to strengthen our oncology portfolio with a promising late-stage, first-in-class global asset to treat gastric cancer,” said Robert Bradway, Amgen’s chairman and CEO.

Five Prime's lead asset is bemarituzumab, a first-in-class, Phase 3 ready anti-FGFR2b antibody that has potential to treat advanced gastric or gastroesophageal junction cancer. Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer, as well as other solid tumors.

A Phase 2 trial also showed a positive correlation between efficacy and expression of FGFR2b on tumor cells, suggesting that FGFR2b could play a role in other epithelial cancers, including lung, breast and ovarian cancers.

Amgen said the acquisition supports its international expansion strategy. Gastric cancer is one of the world's most common forms of cancer and is particularly prevalent in Asia-Pacific, where Amgen expects to generate significant volume growth in the coming years.

The California-based biotech plans to leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumab's potential. As part of the purchase, Amgen will also receive a royalty percentage on future net sales in Greater China from a pre-existing co-development and commercialization agreement between Five Prime and Zai Lab (Shanghai).

Author: Elaine Burridge, Freelance Journalist

Amgen is paying about $1.9 billion for Five Prime Therapeutics, a...
Amgen is paying about $1.9 billion for Five Prime Therapeutics, a clinical-stage biotech focused on targeted cancer therapies. Five Prime's lead asset is bemarituzumab, a potential therapy for advanced gastric or gastroesophageal junction cancer. The deal could close by end June. (c) Amgen

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.